Celladon Corp (NASDAQ:CLDN) Cutting Company Costs After Failure of Heart Treatment Drug Trials

Celladon Corp (NASDAQ:CLDN) is going through a tough phase. The company is cutting out on its workforce to survive after the gene treatment drug for heart disease failed in its Phase 2B trial. The Mydicar drug for curing cardiac diseases failed to help increase survival rate or lower the rate of hospitalization in heart patients, […]